Fjarde AP Fonden Fourth Swedish National Pension Fund Has $18.98 Million Holdings in Allergan PLC. (AGN)

Fjarde AP Fonden Fourth Swedish National Pension Fund raised its holdings in shares of Allergan PLC. (NYSE:AGN) by 1.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 78,056 shares of the company’s stock after purchasing an additional 790 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Allergan PLC. were worth $18,975,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Veritas Asset Management LLP bought a new position in shares of Allergan PLC. during the first quarter valued at approximately $761,339,000. Edgewood Management LLC grew its holdings in shares of Allergan PLC. by 7.0% during the first quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock valued at $646,090,000 after buying an additional 178,055 shares during the last quarter. Epoch Investment Partners Inc. grew its holdings in shares of Allergan PLC. by 3.8% during the first quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock valued at $481,045,000 after buying an additional 73,081 shares during the last quarter. UBS Asset Management Americas Inc. grew its holdings in shares of Allergan PLC. by 0.3% during the first quarter. UBS Asset Management Americas Inc. now owns 1,995,281 shares of the company’s stock valued at $476,713,000 after buying an additional 5,042 shares during the last quarter. Finally, Blue Ridge Capital L.L.C. grew its holdings in shares of Allergan PLC. by 24.1% during the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock valued at $456,313,000 after buying an additional 370,400 shares during the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Allergan PLC. (AGN) opened at 220.29 on Friday. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The company has a market capitalization of $73.64 billion, a P/E ratio of 6.71 and a beta of 1.18. The firm has a 50-day moving average of $231.75 and a 200 day moving average of $236.59.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.95 by $0.07. The business had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the prior year, the firm earned $3.35 EPS. Equities analysts predict that Allergan PLC. will post $16.25 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were issued a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 1.27%. The ex-dividend date of this dividend was Wednesday, August 16th. Allergan PLC.’s dividend payout ratio (DPR) is currently 9.95%.

COPYRIGHT VIOLATION WARNING: This story was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://ledgergazette.com/2017/09/16/fjarde-ap-fonden-fourth-swedish-national-pension-fund-has-18-98-million-holdings-in-allergan-plc-agn.html.

AGN has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price target on the stock in a report on Tuesday, July 11th. BidaskClub upgraded shares of Allergan PLC. from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Royal Bank Of Canada set a $284.00 price target on shares of Allergan PLC. and gave the company a “buy” rating in a report on Monday, June 12th. Mizuho cut their price target on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating on the stock in a report on Friday, June 9th. Finally, Cowen and Company set a $400.00 price target on shares of Allergan PLC. and gave the company a “buy” rating in a report on Thursday, June 8th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have issued a buy rating to the company’s stock. Allergan PLC. currently has an average rating of “Buy” and an average target price of $274.69.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Allergan PLC. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

five × two =